Get started
Author

Faith C. Galderisi

Hemorrhagic disease of the newborn despite vitamin K prophylaxis at birth
2007 · Veronica H. Flood, Faith C. Galderisi, et al. · Pediatric Blood & Cancer · 31
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
2024 · Sarah Nikiforow, Jennifer S. Whangbo, et al. · Blood Advances · 27
PDF
Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
2018 · Paul Harker-Murray, Thierry Leblanc, et al. · Blood · 15
Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia
2009 · Faith Galderisi, Linda Stork, et al. · Pediatric Blood & Cancer · 14
EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
2023 · Lorenzo Falchi, Franck Morschhauser, et al. · Blood · 12
Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
2023 · Joshua Brody, Judit Mészáros Joergensen, et al. · Blood · 10
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
2018 · Ranjana H. Advani, Alison J. Moskowitz, et al. · Blood · 7
Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant
2021 · Susan Prockop, Laurence Gamelin, et al. · Blood · 6
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.
2018 · Jonathan W. Friedberg, Andres Forero-Torres, et al. · Journal of Clinical Oncology · 4
ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia
2025 · Sae Ishimaru, Gwenaëlle Gueguen, et al. · Blood · 2
PDF
High Complete Metabolic Response Rates with Epcoritamab SC + GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
2024 · Joshua Brody, Judit Jørgensen, et al. · Transplantation and Cellular Therapy
In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.
2007 · Faith C. Galderisi, Linda C. Stork, et al. · Blood
Works count: 12
Citation count: 128
H-index: 7
I10-index: 6
Year
Topic
Type